Additional Paid in Capital of Oruka Therapeutics, Inc. from 31 Dec 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
Summary
Oruka Therapeutics, Inc. quarterly Additional Paid in Capital in USD history and change rate from 31 Dec 2010 to 31 Dec 2025.
  • Oruka Therapeutics, Inc. Additional Paid in Capital for the quarter ending 31 Dec 2025 was $657,561,000, a 42% increase year-over-year.
Source SEC data
View on sec.gov
Additional Paid in Capital, Quarterly (USD)
Additional Paid in Capital, YoY Quarterly Change (%)

Oruka Therapeutics, Inc. Quarterly Additional Paid in Capital (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $657,561,000 +$194,543,000 +42% 31 Dec 2025 10-K 12 Mar 2026 2025 FY
Q3 2025 $643,201,000 +$245,856,000 +62% 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $469,998,000 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $466,486,000 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $463,018,000 +$463,017,000 31 Dec 2024 10-K 12 Mar 2026 2025 FY
Q3 2024 $397,345,000 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q4 2023 $1,000* 06 Feb 2024 10-K 06 Mar 2025 2024 FY
Q3 2014 $99,188,000 +$8,845,000 +9.8% 30 Sep 2014 10-Q 12 Nov 2014 2014 Q3
Q2 2014 $99,027,000 +$8,740,000 +9.7% 30 Jun 2014 10-Q 13 Aug 2014 2014 Q2
Q1 2014 $98,835,000 +$26,462,000 +37% 31 Mar 2014 10-Q 13 May 2014 2014 Q1
Q4 2013 $90,498,000 +$19,600,000 +28% 31 Dec 2013 10-Q 12 Nov 2014 2014 Q3
Q3 2013 $90,343,000 +$20,028,000 +28% 30 Sep 2013 10-Q 13 Nov 2013 2013 Q3
Q2 2013 $90,287,000 +$20,785,000 +30% 30 Jun 2013 10-Q 13 Aug 2013 2013 Q2
Q1 2013 $72,373,000 +$2,948,000 +4.2% 31 Mar 2013 10-Q 13 May 2013 2013 Q1
Q4 2012 $70,898,000 +$1,494,000 +2.2% 31 Dec 2012 10-K 20 Mar 2014 2013 FY
Q3 2012 $70,315,000 +$2,470,000 +3.6% 30 Sep 2012 10-Q 13 Nov 2012 2012 Q3
Q2 2012 $69,502,000 +$1,746,000 +2.6% 30 Jun 2012 10-Q 13 Aug 2012 2012 Q2
Q1 2012 $69,425,000 31 Mar 2012 10-Q 14 May 2012 2012 Q1
Q4 2011 $69,404,000 +$4,332,000 +6.7% 31 Dec 2011 10-K 21 Mar 2013 2012 FY
Q3 2011 $67,845,000 30 Sep 2011 10-Q 14 Nov 2011 2011 Q3
Q2 2011 $67,756,000 30 Jun 2011 10-Q 15 Aug 2011 2011 Q2
Q4 2010 $65,072,000 31 Dec 2010 10-K 27 Mar 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.